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Abstract
Introduction The effectiveness of patient education activ-
ities conducted within the lenalidomide and thalidomide
risk evaluation and mitigation strategies (REMS) programs
was evaluated by measuring understanding of serious risk
and safe-use messages.
Methods Results from mandatory knowledge, attitude, and
behavior surveys and voluntary patient surveys completed
between June 2012 and June 2013 were analyzed, and
responses to questions relating to compliance with birth
control measures and understanding of safe-use messages
are presented by patient risk category.
Results In total, 73,645 patients were enrolled into the
REMS programs for lenalidomide and thalidomide and
completed mandatory surveys prior to medication dispense.
Of these, 2790 (3.8%) completed an additional voluntary
survey. Among voluntary survey participants, for all
patient pregnancy risk categories, reported compliance
with birth control requirements was above 90% when
starting therapy and at follow-up. At the beginning of
therapy, complete compliance was 96.3%; 3 months later it
was 96.4%. Patient understanding of safe-use messages
was very high in all pregnancy risk groups, notably for
messages repeated at each physician visit. Overall, 98.2%
of patients knew that lenalidomide and thalidomide could
cause birth defects, which is part of the repeated
educational messaging. In contrast, 87.1% recalled that
unused product should be returned to their healthcare
professional, which is not included in repeated messaging.
Conclusion The lenalidomide and thalidomide REMS
programs enhance patient understanding of safe-use mes-
sages, resulting in high levels of compliance with the birth
control precautions essential to prevent fetal exposure to
these known and potential human teratogens. Overall
compliance was maintained after 3 months of follow-up
and throughout therapy.
Key Points
Regular risk evaluation and mitigation strategies
(REMS) patient survey data indicate high levels of
understanding/retention of REMS safe-use messages.
High compliance rates with REMS program
contraception requirements were also reflected.
1 Introduction
The exposure of thousands of unborn fetuses to thalidomide in
the 1950s and 1960s resulted in major changes to the US
pharmacovigilance and risk management legislation and
regulations [1, 2]. Thalidomide was first marketed in Europe
as a non-barbiturate sedative in the late 1950s, and preclinical
and clinical studies had led to the conclusion that it was non-
toxic in humans [3]. Thalidomide was found to be antiemetic
and was used extensively to treat and prevent ‘morning sick-
ness’ associated with pregnancy. In 1961, two physicians
independently associated thalidomide use in pregnancy with
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congenital malformations including phocomelia, amelia,
syndactyly, and underdeveloped long bones [4, 5]. Fetal
thalidomide exposure has also been associatedwith a range of
internal defects, resulting in an early mortality rate of around
40% [6]. Once the link between thalidomide and birth defects
was established, the drug was withdrawn worldwide and US
pharmaceutical regulatory processes were strengthened [7].
Interest in thalidomide revived when it was shown to be
effective in treating erythema nodosum leprosum (ENL),
an inflammatory reaction that complicates lepromatous
leprosy [8]. Subsequently, thalidomide was found to inhibit
the expression of tumor necrosis factor (TNF), also known
as ‘cachectin’, a cytokine associated with wasting [9]. The
HIV/AIDS community began to use thalidomide to treat
HIV-associated wasting, creating a need to allow access to
thalidomide for those who might benefit, while preventing
access by those who could be at risk from the drug’s ter-
atogenic effects.
In 1998, thalidomide was approved by the US FDA for
acute treatment of the cutaneous manifestations of mod-
erate to severe ENL. Prior to its approval, thalidomide was
found to be anti-angiogenic [10], leading to research into
its use to treat angiomas and malignancies. Subsequent
clinical studies determined thalidomide’s activity in mul-
tiple myeloma (MM) [11, 12]. In 2006, thalidomide
(THALOMID; Celgene Corporation, Summit, NJ, USA)
in combination with dexamethasone was approved by the
FDA to treat newly diagnosed MM.
While Celgene was developing thalidomide, it created
chemical congeners called IMiD products that shared
many of the immune modulatory and other properties of
thalidomide. Celgene discovered that each IMiD product
had slightly different properties from each other and from
thalidomide. The first IMiD product to be commercialized
was lenalidomide (REVLIMID, Celgene Corporation),
which was approved by the FDA in 2005 for the treatment
of transfusion-dependent anemia due to low- or interme-
diate-1-risk myelodysplastic syndromes associated with a
deletion 5q abnormality and in 2006 in combination with
dexamethasone for MM in patients who have received at
least one prior therapy.
The approvals of lenalidomide and thalidomide were
achieved in a different regulatory environment from that of
the 1950s and 1960s and, in tandem with approval of these
drugs, systems were implemented to prevent fetal exposure
[13, 14]. Since the 2007 FDA Amendments Act, the FDA
has required sponsors of new drug applications (NDAs),
biologics license applications (BLAs), generic and
biosimilar applications to submit a risk evaluation and
mitigation strategies (REMS) program if there is concern
that the risks of the product cannot be addressed by routine
product labelling. A REMS program is intended to ensure
that, through the implementation of additional risk-
mitigation measures, the benefits of the drug outweigh the
risks. All REMS programs include a timetable for sub-
mission of assessments, and the FDA may require that a
product-specific REMS program includes a communication
plan, medication guide, patient package insert, ‘elements to
assure safe use’ (ETASU), and an implementation system.
Lenalidomide and thalidomide have REMS programs
with ETASUs that have two goals: (1) to prevent the risk of
embryo-fetal exposure and (2) to inform prescribers,
patients, and pharmacists of the serious risks and safe-use
conditions of the product. To achieve these goals, some key
safe-use messages in the REMS programs are repeated at
each physician visit. The repeated messages vary according
to patient risk categories but include warnings on birth
defects, sexual intercourse, birth control, drug sharing, and
donations to blood and sperm banks.
One of the ETASU measures introduced to achieve these
goals is to ensure the product is dispensed to patients enrolled
in the REMS only after they have received, and confirm they
understand, comprehensive safe-use education messages and
agree to participate in frequent mandatory knowledge, atti-
tude, and behavior (KAB) surveys. Additional voluntary
patient surveys were conducted up to 2013 to examine patient
understanding and compliance with safe-use measures.
While the FDA has been able to mandate REMS pro-
grams since 2007, published data available on the effec-
tiveness of these programs are limited. In an evaluation of
REMS medication guides, 30.3% of medication guide
assessments led to ‘acceptable knowledge’ (C80% correct
responses), with higher correct response rates reported for
REMS programs including ETASUs [15]. Previous analy-
sis of voluntary survey data from the lenalidomide
RevAssist risk management program (from 2006) repor-
ted over 95% comprehension of safe-use messaging for
male patients and females of childbearing potential [14].
This study was conducted to evaluate the effectiveness of
patient education activities in the lenalidomide and
thalidomide REMS programs by analyzing the results of the
mandatory KAB surveys and additional voluntary patient
surveys to assess comprehension of safe-use messages and
patient-reported compliance with birth control measures.
2 Methods
The surveys described here were conducted in support of a
regulatory commitment of the REMS programs to serve as
a practical indicator of safe-use conditions rather than for
research purposes. Mandatory surveys from June 2012 to
June 2013 were interrogated alongside data from the vol-
untary surveys from June 2012 to February 2013 to
establish receipt of patient brochures, patient understanding
of safe-use messages, and reported compliance with birth
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control requirements. Demographic data were collected for
both survey populations.
2.1 Lenalidomide and Thalidomide Risk Evaluation
and Mitigation Strategies (REMS) Program
The main elements of the Celgene REMS programs are
presented in Fig. 1. Every prescriber intending to prescribe
lenalidomide or thalidomide must first become certified
into the respective REMS program. A certified prescriber
may then enroll patients into the REMS program in a
similar manner. The prescriber provides the patient with
educational material highlighting the serious risks and safe-
use conditions of the product and describes the frequent
interactions with the REMS program during therapy. All
patient materials were written to be comprehensible by a
patient at 8th grade literacy levels. The prescriber and
patient choose a unique identifier that is used in future
REMS interactions, and information about the patient risk
category, age, and indication is recorded in the Celgene
REMS database. Throughout therapy, both the prescriber
and the patient are required to provide the REMS program
Registers in REMS program
and cerﬁed by Celgene
Paent counselled on beneﬁts and risks of therapy. 
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Fig. 1 Flowchart highlighting
the main components of the
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with information that confirms continued patient under-
standing of the safe-use measures before each subsequent
prescription can be filled.
The safe-use messages provided to patients prior to
enrollment into the REMS program are as follows: (1)
these products can cause birth defects, (2) contraceptive
measures must be taken while receiving therapy, (3) these
drugs cannot be shared, (4) patients must not donate
blood to a blood bank, (5) any unused product must be
returned to a healthcare professional. This information is
described in patient brochures and in the patient–physi-
cian agreement form (PPAF) that is signed by patients
and returned to Celgene. The PPAF also includes patient
demographics and International Classification of Diseases
(ICD) diagnosis codes, which are provided by the pre-
scriber. The serious risk messages are also conveyed in
the prescriber brochure to ensure prescribers are suffi-
ciently informed to educate their patients about the risks
before initiating therapy. Safe-use messages appropriate to
the patients’ risk categories are repeated at each physician
visit.
Other patient resources include a patient resource kit,
which contains a REMS patient guide and an emergency
contraception brochure. These materials are provided to
the patient at the time of enrollment by the prescriber in
support of the PPAF discussion. They are also available
publicly on the REMS websites (http://www.
revlimidrems.com for lenalidomide; http://www.
thalomidrems.com for thalidomide). Additionally, each
patient is counseled by a REMS-certified counselor with a
REMS Education and Counseling Checklist for Pharma-
cies before each dispense.
Importantly, lenalidomide and thalidomide are dis-
pensed to patients enrolled in the REMS only after they
have received, and confirmed they understand, compre-
hensive safe-use messages. All patients must agree to
participate in frequent KAB surveys initially, as well as
during treatment, with the frequency depending on patient
risk category. These surveys may be taken online, via an
interactive voice-response system, or by calling the Cel-
gene Customer Care Center. Mandatory surveys occur
monthly for boys, men, girls who have not undergone
menarche, and females of reproductive potential, and every
6 months for women not of reproductive potential. The
number and nature of questions varies between risk cate-
gories. Mandatory surveys for adult males and females of
reproductive potential include questions on the use of birth
control methods and drug sharing. The survey for females
of reproductive potential also includes questions that con-
firm their risk category, obtains confirmation of accept-
able contraception behaviors as outlined by REMS, and
affirms the patient understands the potential for the product
to cause birth defects.
Mandatory surveys are also completed by prescribers
when a prescription is written. Prescriber surveys include
questions on contraception counselling, pregnancy testing,
and drug prescribing. All mandatory surveys for patients
and prescribers are reviewed using a computer algorithm
that ‘flags’ discrepant responses that indicate a potential
cause for concern. Responses were identified as discrepant
if (1) they diverged from the desired answers or (2) there
was discrepancy between patient and prescriber responses.
If a flag occurs to halt the REMS authorization process, an
outbound call from Celgene is placed to the prescriber to
provide the appropriate patient information to remedy the
flag and verify safe-use conditions. All flags must be
resolved prior to drug dispense.
2.2 Voluntary Patient Survey
Patients in the REMS program indicated on the PPAF
whether they would be willing to participate in additional
voluntary surveys (an initial survey for patients B14 days
from initial dispense and a follow-up for patients[90
days from enrollment) that further examined their
understanding and compliance with safe-use measures in
relation to the REMS program. The patients who volun-
teered were categorized into one of four risk categories
(children, females of childbearing potential, females not
of childbearing potential, and adult males). Of these
patients, one child (if available) and at least 77 other
patients were randomly selected each week for the vol-
untary patient population. All eligible females of child-
bearing potential were included in the initial survey,
whereas one-third of eligible females of childbearing
potential were included in the follow-up survey (with no
minimum or maximum number for patients in this cate-
gory in either survey). The remaining patients were ran-
domly selected from the females not of childbearing
potential (40%, minimum of four patients) and adult
males (60%, minimum of six patients).
The survey queried patients whether they were provided
with the REMS program education materials and engaged
in sufficient conversations with their healthcare providers
to understand the contents. Patients were then classified
into pregnancy risk groups similar to those in the manda-
tory KAB survey. Short- and long-term understanding and
retention of educational materials was evaluated by sam-
pling patients within 14 days of the first lenalidomide or
thalidomide prescription (short-term retention) and after
they had received therapy for at least 3 months (long-term
retention).
The voluntary surveys also assessed patient compli-
ance with birth control requirements. Acceptable forms
of birth control for patients receiving lenalidomide and
thalidomide include true abstinence or one highly
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effective and one additional effective method of con-
traception. Highly effective contraception methods
include an intrauterine device, hormonal birth control
pills or devices, tubal ligation, or partner’s vasectomy.
Additional effective methods include male condom,
diaphragm, or cervical cap. The THALOMID (thalido-
mide) voluntary patient survey for female patients of
childbearing potential is provided in the Electronic
Supplementary Material.
Information provided during enrollment into the
mandatory REMS program and the optional voluntary
patient survey, together with the results from the manda-
tory surveys, was analyzed to determine the effectiveness
of patient education activities.
3 Results
3.1 Patients in the REMS Programs
Between June 2012 and June 2013, a total of 73,645
patients enrolled into the REMS programs, including
56,709 patients receiving lenalidomide and 16,936 patients
receiving thalidomide. The vast majority of patients
(82.9%) enrolled in the REMS were treated for MM, with
lower numbers of patients treated for myelodysplastic
syndrome (6.4%), ENL (0.1%), and other conditions
(10.5%).
The distribution of patients by risk category is summa-
rized in Fig. 2a. Consistent with published epidemiological
Fig. 2 Characteristics of the
patient populations.
a Distribution of patients
enrolled in the lenalidomide and
thalidomide Risk Evaluation
and Mitigation Strategies
(REMS) programs between June
2012 and June 2013 by risk
category (N = 73,645).
b Distribution of patients in the
voluntary survey population by
risk category (N = 2790).
C Proportion of patients in the
voluntary survey population
who received and read the
patient education brochure by
risk category
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data for MM [16], there were more males (40,774 [55.4%])
than females (32,871 [44.6%]). Of the female patients,
2216 (6.7%) were of reproductive potential, and the
majority (93.1%) were adult females not of reproductive
potential, indicating the older population expected for
patients with the diseases associated with the use of these
drugs. Children represented\1% of the enrolled patients.
Of the 73,645 patients enrolled in the REMS programs,
10,391 (14.1%) agreed to participate in the additional
voluntary survey. Of these, 3981 patients were randomly
selected for inclusion in the voluntary survey sample, of
whom 2790 (70.1%) responded. The distribution of
responding patients is presented by risk category in Fig. 2b.
The proportion of patients in each risk category was gen-
erally consistent with those recorded for the whole popu-
lation enrolled in the REMS programs (Fig. 2a), with more
females of reproductive potential, as expected from the
sampling strategy used (see Methods). The voluntary sur-
vey confirmed that 89.4% of patients received the initial
education materials from their healthcare professional and
85.9% read them before starting treatment with lenalido-
mide or thalidomide (Fig. 2c).
During the study period, 264,417 mandatory patient
surveys were performed and 14,848 (5.6%) were flagged as
a potential cause for concern (Table 1). Females of
reproductive potential had the highest number of flagged
surveys (6062 [45.0%]), all of which were resolved before
the patient received her prescription. Follow-up determined
that 696 (11.5%) were due to the patient not understanding
or not complying with risk/safe-use messages. These
reports were investigated and resolved prior to drug dis-
pense, as described in the Methods section. A further 4025
(66.4%) of the surveys for females of reproductive poten-
tial were flagged because, since their initial enrollment into
the REMS program, the patient had either had their uterus
removed, or their menstrual periods had stopped for more
than 24 months. These patients were re-classified as
females not of reproductive potential.
The voluntary surveys for the same period indicated that
97.9% of the women of reproductive potential and adult
females not of reproductive potential (n = 1126) surveyed
understood that women should not get pregnant while
taking the product, and 94.0% complied with birth control
requirements at initial survey (91.2% at follow-up),
demonstrating the effectiveness of these interventions in
ensuring patient understanding of, and compliance with,
safe-use messages.
3.2 Compliance with Birth Control Requirements
Patient-reported compliance with pregnancy-prevention
measures was determined in the voluntary survey. Com-
pliance with the required two forms of birth control was
assessed when starting therapy and 3 months later
(Table 2). Reported birth control compliance was high:
96.3% of patients used the required birth control when
starting therapy, and 96.4% reconfirmed this later.
3.3 Understanding of Safe-Use Messages
The impact of repeated educational messages on patient
understanding and compliance with safe-use messages was
assessed by reviewing surveys conducted in the voluntary
survey population several months after starting therapy
(Table 3).
Overall understanding of safe-use messages was very
high: around 98% of patients demonstrated an under-
standing of most of these messages. Importantly, 98.2% of
patients knew that lenalidomide and thalidomide can cause
birth defects, which is part of the repeated educational
Table 1 Distribution of risk evaluation and mitigation strategies (REMS) patient survey flags by pregnancy risk category (June 2012–June 2013)
Risk category Surveys completed (N) Number (%) of surveys flagged
Females of reproductive potential (adult and child) 13,481 6062 (45.0)
Females not of reproductive potential (adult and child) 33,364 5289 (15.9)
Males (adult and child) 217,572 3497 (1.6)
Total 264,417 14,848 (5.6)









Females of reproductive potential 233 219 (94.0) 147 134 (91.2)
Males (adult and child) 1532 1480 (96.6) 1443 1399 (97.0)
Total 1765 1699 (96.3) 1590 1533 (96.4)
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messaging, whereas 87.1% recalled that unused product
should be returned to their healthcare professional, which is
not included in repeated messaging (Table 3).
4 Discussion
Effectiveness of the REMS programs for lenalidomide
and thalidomide in driving patient understanding and
retention of safe-use messages was assessed using data
from mandatory KAB assessments and voluntary patient
surveys. Patients surveyed had high levels of compliance
with birth control requirements, both initially and at fol-
low-up, as well as very high levels of understanding of
safe-use messages. This study determined that mandated
REMS programs are effective tools for educating patients
in the safe use of lenalidomide and thalidomide and re-
enforcing compliance with safe-use measures by repeated
messaging. Previous studies have determined that levels
of fetal exposure to both lenalidomide and thalidomide
are very low in patients enrolled in US risk management
programs for these drugs [13, 14]. A third Celgene IMiD
product, pomalidomide (Pomalyst, approved in the USA
for advanced MM in 2013) is distributed through an
REMS identical to that for lenalidomide. It is anticipated
that the REMS program will be similarly effective for this
product.
Patient understanding of safe-use messages in the Cel-
gene REMS programs reported in this study (approxi-
mately 98% for key messages related to pregnancy,
teratogenicity, and sharing the product) is consistent with
the high levels of understanding reported in a previous
analysis of voluntary surveys conducted as part of the
original lenalidomide risk management program (RevAs-
sist) [14]. However, published data on the effectiveness of
messaging in other REMS programs are limited. A recent
study investigating patient understanding of key risks based
on medication guide assessments for 66 drugs between
September 2008 and June 2012 found that primary drug
risk knowledge questions were answered correctly by
63.8% of respondents on average [15]. Higher rates were
recorded for REMS that also included ETASU or a com-
munication plan and ETASU (89.8 and 82.7%, respec-
tively). The continued high understanding of safe-use
messages for patients in the Celgene REMS programs is
consistent with the higher rate of patient understanding in
REMS programs with ETASUs and indicates the relative
effectiveness of the Celgene programs.
The high reported adherence to birth control measures
for the Celgene REMS programs is particularly important
given the teratogenic potential of the drugs involved.
Thalidomide is a proven human teratogen, and lenalido-
mide caused thalidomide-like malformations in newborn
monkeys in pre-clinical studies. Therefore, both must be
considered products with teratogenic potential [17]. A
limitation of the current study is that the surveys do not
report on patient behavior, which may not necessarily
reflect survey responses. In a study of oral contraception
use in over 6 million US women of childbearing age, only
59.8% of those receiving both category X medications and
oral contraceptives were considered to be adherent to oral
contraception [18]. Consequently, an estimated 5.8% of
pregnancies in the USA occur in women receiving medi-
cations of known teratogenic risk (categories D or X) [19].
In this context, the high reported adherence to birth control
requirements in this study (consistently over 90%) indi-
cates the effectiveness of repeated messaging enabling
understanding of birth control requirements in the REMS
programs for lenalidomide and thalidomide. Crucially,
Celgene risk management measures have been executed
over 18 years, with no reported births with teratogenicity
due to Celgene products.














Total surveyed 147 979 1441 2 7 2576
Product can cause birth defects 146 958 1417 2 7 2530 (98.2)
Sharing product with others can be
dangerous
146 969 1417 2 7 2541 (98.6)
Women should not get pregnant
while taking product
144 958 – – – 1102 (97.9)
Men should use condoms while on
product if they are sexually active
with a woman who is able to
become pregnant
– – 1418 2 – 1420 (98.4)
Unused product needs to be returned 129 866 1239 2 7 2243 (87.1)
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In this study, understanding was particularly high for
safe-use messages that were part of repeated messaging.
For each of these safety messages, around 98% of patients
demonstrated understanding, considerably higher than for a
message not included in repeated messaging (Table 3).
This demonstrates the crucial role of repeated messaging in
the REMS programs, particularly for messages related to
teratogenicity and the need for adequate birth control
measures. The high rate of understanding of these mes-
sages is reflected in a high rate of reported adherence to
birth control measures. Repeated messaging has previously
been shown to be effective in influencing prescriber
behavior in a study of the provision of calcium and vitamin
D supplements to UK patients receiving anti-epileptic
drugs [20]. In the Celgene REMS programs, the use of
mandatory monthly (for patients of reproductive potential)
or 6-monthly (for other patients) KAB surveys allows
patients’ continued understanding of safe-use messages to
be regularly and continually assessed prior to dispensing.
Approximately 5% of the 264,417 surveys completed
during this study were flagged, providing the opportunity to
investigate and resolve concerns before lenalidomide or
thalidomide was dispensed.
It should be noted that the surveys described here were
conducted in support of a regulatory commitment of the
REMS programs to serve as a practical indicator of safe-
use conditions rather than for research purposes. Conse-
quently, the goals and objectives of these surveys differ
from those of surveys conducted as purely research exer-
cises. One limitation of this study is the limited duration of
follow-up. Messaging within REMS programs needs to be
developed to prevent patient ‘fatigue’ with repeated mes-
saging [21], which could potentially diminish patients’
attention to serious risk and safe-use messaging. There was
no evidence in this study that the repeated messaging in the
lenalidomide and thalidomide REMS programs led to a
reduction in patients’ attention to safety messages; how-
ever, there was no follow-up beyond 3 months. Additional
studies are required to assess whether repeated messaging
leads to diminution of patient attention.
In addition, although analysis of the patient surveys
allowed us to assess patient understanding of REMS
messaging, it did not provide any data on the impact of the
REMS programs on prescribers. We believe that the results
presented in this report, the record of birth control com-
pliance with other category X drugs, and the overarching
REMS programs rationale should be considered when
evaluating the burden incurred by healthcare providers in
relation to REMS programs. In a survey of 364 healthcare
providers in Southern California, USA, most respondents
(63%) considered that REMS improved patient safety,
whereas 62% considered that REMS was very or somewhat
meaningful in improving patient safety. Among oncology
prescribers (N = 28), 68% considered that REMS
improved patient safety, whereas 75% responded that
REMS was meaningful [22]. Despite this, the additional
administrative burden incurred by REMS programs is a
recognized concern among oncology practitioners [21, 23].
To mitigate this, online enrollment systems have been
developed to minimize the administrative burden on
healthcare providers enrolling patients in the REMS pro-
grams for lenalidomide and thalidomide [24]. Further
studies are required to assess the burden of REMS pro-
grams and to evaluate potential improvements to the
REMS process.
The necessary extra administrative burden incurred by
these REMS programs must be considered in the context of
the risk of fetal exposure and the effectiveness of the
programs in preventing this exposure. Data presented here
and elsewhere [13, 14] clearly demonstrate that these
programs drive the high levels of patient understanding and
compliance necessary to prevent fetal exposure.
5 Conclusion
Lenalidomide and thalidomide are both important treat-
ments for an increasing variety of malignant conditions.
For these and other teratogenic compounds to be used
safely, it is crucial that both the pharmaceutical industry
and regulatory authorities work to minimize the risk of
fetal exposure. The data from this study support the con-
clusion that the lenalidomide and thalidomide REMS pro-
grams in the USA enhance patient understanding of safe-
use messages, leading to high levels of compliance with the
birth control precautions essential to prevent fetal exposure
to these known and potential human teratogens. The
3-month follow-up with the voluntary survey means there
are no data on longer-term patient understanding of the
REMS. However, the mandatory surveys show that overall
compliance was maintained after 3 months of follow-up
and throughout therapy.
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